SPLITOAK STRATEGIES LLC for CARIS LIFE SCIENCES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act; HR 2617 Consolidated Appropriations Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN | Special Assistant to the President for Legislative Affairs; Assistant to the Speaker for Policy; Legislative Assistant; Policy Analyst |
Medical/Disease Research/Clinical Labs MED
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 2617 Consolidated Appropriations Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN | — |
Health Issues HCR
The Valid Act and appropriate regulatory structure for advanced molecular and genomic testing, HR 2617 Consolidated Appropriations Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN | — |
Copyright/Patent/Trademark CPT
Strengthen the patent system for advanced molecular cancer diagnostic tests; S 4734 Patent Eligibility Restoration Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN | Special Assistant to the Speaker for Policy; Special Assistant to the President for Legislative Affairs; Policy Analyst; Legislative Assistant |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.